

TAT GIDA SANAYİ A.Ş.

**CONDENSED FINANCIAL STATEMENTS FOR THE
INTERIM PERIOD JANUARY 1 - JUNE 30, 2025
TOGETHER WITH INDEPENDENT AUDITOR'S
REVIEW REPORT**



**CONVENIENCE TRANSLATION INTO ENGLISH OF INDEPENDENT
AUDITOR'S REVIEW REPORT ORIGINALLY ISSUED IN TURKISH**

**REPORT ON REVIEW OF INTERIM CONDENSED
FINANCIAL INFORMATION**

To the General Assembly of Tat Gıda Sanayi A.Ş.

Introduction

We have reviewed the accompanying statement of financial position of Tat Gıda Sanayi A.Ş. (the "Company") as at 30 June 2025 and the related statements of profit or loss and other comprehensive income, changes in equity and cash flows for the six-month period then ended. The management of the Company is responsible for the preparation and fair presentation of this interim financial information in accordance with Turkish Accounting Standard 34 ("TAS 34") "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of interim financial information performed by the independent auditor of the entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and the objective of which is to express an opinion on the financial statements. Consequently, a review on the interim financial information does not provide assurance that the audit firm will be aware of all significant matters which would have been identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to conclude that the accompanying interim financial information is not prepared, in all material respects, in accordance with TAS 34.

PwC Bağımsız Denetim ve
Serbest Muhasebeci Mali Müşavirlik A.Ş.

Cihan Harman, SMMM
Independent Auditor

Istanbul, 11 August 2025

INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION	1-2
INTERIM CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	3
INTERIM CONDENSED STATEMENT OF CHANGES IN EQUITY	4
INTERIM CONDENSED STATEMENT OF CASH FLOWS	5
EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS	6-31

TAT GIDA SANAYİ A.Ş.**INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION
AS OF 30 JUNE 2025**

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

		Reviewed	Audited
Assets	Notes	30 June 2025	31 December 2024
Current Assets			
Cash and cash equivalents		1,030,637,803	137,241,800
Trade receivables		1,415,773,996	1,201,059,786
-Trade receivables from related parties	4.16	43,211,918	27,499,548
-Trade receivables from third parties	4	1,372,562,078	1,173,560,238
Other receivables		7,254,448	3,343,377
-Other receivables from related parties		7,254,448	3,343,377
Inventories	5	2,271,525,586	4,200,737,922
Prepaid expenses		345,697,259	72,771,733
Other current assets	15	252,113,324	429,648,652
Total Current Assets		5,323,002,416	6,044,803,270
Non-Current Assets			
Other receivables		68,085	79,437
-Other receivables from third parties		68,085	79,437
Financial investments		3,938,830	3,938,833
Property, plant and equipment	6	2,570,843,622	2,537,226,908
Right of use assets		218,458,788	224,858,530
Intangible assets		201,627,479	166,861,441
Other non-current assets	15	33,121,334	5,008,395
Total Non-Current Assets		3,028,058,138	2,937,973,544
Total Assets		8,351,060,554	8,982,776,814

The accompanying notes form an integral part of these financial statements.

TAT GIDA SANAYİ A.Ş.**INTERIM CONDENSED STATEMENTS OF FINANCIAL POSITION
AS OF 30 JUNE 2025**

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

		Reviewed	Audited
Liabilities	Notes	30 June 2025	31 December 2024
Short term liabilities			
Short term financial borrowings	3	2,372,208,871	2,050,507,806
Short term leasing borrowings	3	20,919,807	23,751,317
- Short term leasing borrowings to related parties		3,328,959	545,930
- Short term leasing borrowings to third parties		17,590,848	23,205,387
Short term portion of long-term borrowings	3	724,211,968	1,066,297,833
Trade payable		680,492,458	1,052,540,166
- Trade payables to related parties	4.16	20,985,615	9,298,733
- Trade payables to third parties	4	659,506,843	1,043,241,433
Employee benefit obligations		59,041,938	78,705,546
Other payables		26,361,469	87,996,918
- Other payables from related parties	16	-	70,934,162
- Other payables from third parties		26,361,469	17,062,756
Deferred income		57,092,094	83,710,421
Short-term provisions		87,517,673	44,823,856
- Short term provisions for employment benefits		16,374,855	11,670,703
- Other short term provisions		71,142,818	33,153,153
Total short term liabilities		4,027,846,278	4,488,333,863
Long term liabilities			
Long term financial borrowings	3	521,754,547	604,750,968
Long term leasing borrowings	3	77,960,020	98,805,634
-Long term leasing borrowings to third parties		77,960,020	98,805,634
Deferred tax liabilities		25,945,474	124,416,484
Long term provisions		62,510,980	64,778,500
- Long term provisions for employment benefits		62,510,980	64,778,500
Total long term liabilities		688,171,021	892,751,586
Total liabilities		4,716,017,299	5,381,085,449
Equity of the parent company			
Share capital	8	244,800,000	136,000,000
Inflation adjustment to share capital	8	3,320,174,466	3,308,115,074
Share premiums/discounts	8	77,256,321	--
Other comprehensive income or expenses that may be reclassified subsequently to profit or loss		(365,201,079)	(293,297,563)
- Financial assets revaluation reserve			
- Losses related to hedging from flow risk		(365,201,079)	(293,297,563)
Other comprehensive income or expenses that will not be reclassified subsequently to profit or loss		(108,212,140)	(108,280,077)
- Actuarial losses in defined benefit plan		(108,212,140)	(108,280,077)
Restricted reserves	8	1,032,112,393	1,032,112,393
Previous years' losses		(472,958,462)	--
Net Period Loss		(92,928,244)	(472,958,462)
Equity of the parent company		3,635,043,255	3,601,691,365
Total equity		3,635,043,255	3,601,691,365
Total liabilities and equity		8,351,060,554	8,982,776,814

The accompanying notes form an integral part of these financial statements.

TAT GIDA SANAYİ A.Ş.

INTERIM CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR 30 JUNE 2025 AND 31 DECEMBER 2024

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

		Reviewed 1 January- 30 June 2025	Reviewed 1 January- 30 June 2024	Reviewed 1 April- 30 June 2025	Reviewed 1 April- 30 June 2024
Notes					
Profit or Loss					
Sales	9	3,515,905,621	4,139,180,635	1,691,983,299	1,883,898,339
Cost of sales (-)	9	(3,122,698,092)	(3,836,598,287)	(1,460,682,181)	(1,719,638,877)
Gross profit		393,207,529	302,582,348	231,301,118	164,259,462
Marketing expenses (-)	10	(234,483,247)	(354,845,973)	(115,642,856)	(144,029,772)
General administrative expenses (-)	10	(200,207,363)	(318,793,087)	(101,533,740)	(127,729,927)
Research and development expenses (-)	10	(10,955,735)	(16,540,760)	(5,729,489)	(8,876,385)
Other income from operating activities	11	223,929,808	355,696,252	111,166,078	163,558,717
Other expenses from operating activities (-)	11	(78,055,374)	(118,948,070)	(38,732,700)	(53,246,420)
Operating profit/loss		93,435,618	(150,849,290)	80,828,411	(6,064,325)
Income from investing activities	12	270,642	10,028,362	96,970	6,914,294
Operating profit before finance income/(expense)		93,706,260	(140,820,928)	80,925,381	849,969
Finance income	13	100,882,449	43,956,906	72,092,211	21,443,134
Finance expense (-)	13	(709,680,225)	(784,270,768)	(339,895,857)	(387,166,705)
Financing expenses, net		(608,797,776)	(740,313,862)	(267,803,646)	(365,723,571)
Net monetary gains		352,180,542	373,307,132	100,042,104	(13,479,041)
Profit (Loss) before tax		(162,910,974)	(507,827,658)	(86,836,161)	(378,352,643)
Tax expense		69,982,730	(44,284,155)	77,926,527	3,438,735
- Current tax expense	14	-	-	-	1,300,213
- Deferred tax income(Loss)	14	69,982,730	(44,284,155)	77,926,527	2,138,522
Period loss		(92,928,244)	(552,111,813)	(8,909,634)	(374,913,908)
Earnings per share		(0.38)	(4.06)	(0.04)	(2.76)
Diluted gain per share from continuing operations (kurus)		(0.38)	(4.06)	(0.04)	(2.76)
Other comprehensive income:		(71,835,579)	103,438,575	(37,808,616)	(23,641,716)
Actuarial gains (losses) from revaluation or reclassification of investments using equity method		-	146,077,279	-	(12,872,097)
Expense (income) relating to avoidance of risk of cash flow		(71,903,516)	(16,361,417)	(40,604,492)	11,065,631
Actuarial gains /(losses) on employee benefits		67,937	(26,277,287)	2,795,876	(21,835,250)
Total other comprehensive income/expense		(71,835,579)	103,438,575	(37,808,616)	(23,641,716)
Total comprehensive expense		(164,763,823)	(448,673,238)	(46,718,250)	(398,555,624)

The accompanying notes form an integral part of these financial statements.

TAT GIDA SANAYİ A.Ş.

INTERIM CONDENSED STATEMENT OF CHANGES IN EQUITY FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025)

				Other Comprehensive Income Reclassified to Profit or Loss	Other Comprehensive Income Not to Be Reclassified to Profit or Loss					
	Share Capital	Inflation adjustments to share capital	Share premium/discount	Financial assets revaluation reserve	Hedging related to cash flow risk	Actuarial gain/(losses) in defined benefit plans	Restricted profit reserves	Net profit for the Period	Retained earning	Total equity
Balance as at 1 January 2024	136,000,000	3,823,285,305	223,053,054	(146,077,279)	(276,619,208)	(83,143,603)	1,096,136,152	(145,275,602)	(657,134,511)	3,970,224,308
Transfers(*)	-	(515,295,699)	(223,053,054)	-	-	-	(64,061,360)	145,275,602	657,134,511	-
Total comprehensive income	-	-	-	146,077,279	(16,361,417)	(26,277,287)	-	(552,111,813)	-	(448,673,238)
Balance as at 30 June 2024	136,000,000	3,307,989,606	-	-	(292,980,625)	(109,420,890)	1,032,074,792	(552,111,813)	-	3,521,551,070
Balance as at 1 January 2025	136,000,000	3,308,115,074	-	-	(293,297,563)	(108,280,077)	1,032,112,393	(472,958,462)	-	3,601,691,365
Transfers	-	-	-	-	-	-	-	472,958,462	(472,958,462)	-
Capital Increase	108,800,000	12,059,392	77,256,321	-	-	-	-	-	-	198,115,713
Total comprehensive income	-	-	-	-	(71,903,516)	67,937	-	(92,928,244)	-	(164,763,823)
Balance as at 30 June 2025	244,800,000	3,320,174,466	77,256,321	-	(365,201,079)	(108,212,140)	1,032,112,393	(92,928,244)	(472,958,462)	3,635,043,255

(*) With the decision of the general assembly held on 25 April 2024, it was decided to transfer the previous year losses. According to this decision, capital adjustment differences amounting to TRY515,295,699, share capital adjustment differences amounting to TRY223,053,054 issue premiums/discounts, TRY64,061,360 restricted reserves transferred from retained earnings.

The accompanying notes form an integral part of these financial statements.

TAT GIDA SANAYİ A.Ş.

INTERIM CONDENSED STATEMENT OF CASH FLOWS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 31 December 2024.)

	Notes	Reviewed 1 January- 30 June 2025	Audited 1 January- 30 June 2024
Period loss / (profit)		(92,928,244)	(552,111,813)
Adjustments to reconcile profit (loss) for the period			
Adjustments related to depreciation and amortization expenses		74,380,037	84,825,535
Adjustments related to impairment of stocks	5	(11,602,658)	(4,853,965)
Adjustments related to provisions		65,802,076	52,554,421
Adjustments related to provision for employee termination benefit		16,702,436	6,281,088
Adjustments related to other provisions		49,099,640	46,273,333
Adjustments related to gain or loss on sales of property, plant and equipment	12	(270,642)	5,652,522
Adjustments related to income accruals		-	3,175,228
Adjustments related to tax expense	14	(69,982,730)	44,284,155
Unrealized foreign exchange loss		188,824,684	51,620,885
Discount expense		(17,943,659)	(1,018,887)
Discount income		19,923,129	43,061,577
Interest income	13	(100,882,449)	(27,397,499)
Interest expense	13	448,952,025	671,266,392
Monetary Gain Loss Adjustments		(393,850,375)	(582,805,938)
Changes in working capital		110,421,194	(211,747,387)
Adjustments related to changes in trade receivables and other receivables		(225,688,192)	(1,376,936,332)
Adjustments related to changes in due from related parties		(15,712,370)	1,685,650,638
Adjustments related to changes in inventories		1,937,929,893	2,456,483,566
Adjustments related to changes in prepaid expenses		(272,925,526)	(436,411,905)
Adjustments related to changes in other current and non-current assets		129,583,427	289,245,897
Adjustments related to changes in trade payables		(365,790,930)	(473,428,463)
Adjustments related to changes due to related parties		11,686,882	(44,092,879)
Adjustments related to changes in deferred income		(26,618,327)	(56,928,212)
Decreases in employee benefit payables		(19,663,608)	9,617,038
Adjustments related to changes in other current liabilities		(90,146,375)	1,534,328
Cash flows from operating activities		1,173,076,068	1,842,986,289
Employee termination benefits paid		(4,723,741)	(43,230,962)
Taxes paid		-	30,817,918
Net cash flows (used in)/from operating activities		1,168,352,327	1,830,573,245
Investing activities:			
Property, plant and equipment and intangible asset acquisitions		(126,854,819)	(106,183,107)
Cash generated from sale of property, plant and equipment and intangible assets		324,954	4,624,810
Interest received		100,882,449	27,397,500
Net cash used in investing activities		(25,647,416)	(74,160,797)
Financing activities			
Cash outflow due to leasing		(29,717,148)	(26,529,290)
Cash inflows due to loan received		1,756,245,644	1,644,871,109
Cash outflows due to loan received		(1,632,836,702)	(1,886,103,890)
Interest paid		(521,503,050)	(638,990,246)
Cash inflows from share issuance or capital increase		198,115,713	-
Net cash from financing activities		(229,695,543)	(906,752,317)
Effect of monetary loss on cash and cash equivalents		(19,613,365)	(415,122,715)
Net change in cash and cash equivalents		893,396,003	434,537,416
Cash and cash equivalents at the beginning of the period		137,241,800	156,133,840
Cash and cash equivalents at the end of the period		1,030,637,803	590,671,256

The accompanying notes form an integral part of these financial statements.

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 1 - ORGANISATION AND OPERATIONS OF THE COMPANY

Tat Gıda Sanayi A.Ş. ("Tat Gıda" or "the Company") was established in 1967 with the name Tat Konserve Sanayi A.Ş., the name change of the Company was decided at the extraordinary assembly meeting on 30 October 2013 and registered on 15 November 2013. The Company is engaged in the production, distribution, marketing, domestic and foreign trade and brokerage of semi-finished and finished food; merchandise goods, food, beverage, juice, agricultural and animal products, frozen foods, dried goods, including pulverized goods and raw and primitive form of materials recipient and additives, sweet and sugar free juice and canned goods. The Company is incorporated in Turkey and operates in accordance with the Turkish Commercial Code.

As of 30 June 2025 and 31 December 2024, the number of employees employed by the Company is as follows:

	30 June 2025		31 December 2024	
	End of Period	Average	End of Period	Average
Permanent Personnel	445	439	427	435
Temporary Personnel	630	404	308	575
Total	1,075	843	735	1,010

The registered head office address is as follows

Taşdelen Mah. Sırrı Çelik Bulvarı No:7
34788 Çekmeköy / İstanbul / Türkiye

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS

Principles of measurement

Measurement principles

The interim condensed financial statements have been prepared in Turkish Lira (TL) on the historical basis cost principle, except for derivative instruments measured at fair value. In determining historical cost, the fair value of the amount paid for assets is generally taken into account. The financial statements have been prepared based on the historical cost basis adjusted for inflation effects, as of 31 December 2004.

Reporting and Functional Currency

The financial statements are presented in the currency of the primary economic environment in which the entity operates (its functional currency). For the purpose of the financial statements, the functional and presentation currency of the Company is TRY.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)**2.1 Basic Principles of Presentation (Continued)**

Pursuant to the Capital Markets Board (CMB) decision dated 28 December 2024 and numbered 81/1820, based on the announcement made by POA on 23 November 2024 and the "Implementation Guide on Financial Reporting in Hyperinflationary Economies" published on 23 November 2024, it has been decided that issuers and capital market institutions subject to financial reporting regulations applying Turkish Accounting/Financial Reporting Standards shall apply inflation accounting by applying the provisions of TAS 29 starting from their annual financial reports for the accounting periods ending on 31 December 2024.

As of 30 June 2025, adjustments were made to reflect changes in the general purchasing power of the Turkish Lira in compliance with the requirements of TAS 29 ("Financial Reporting in Hyperinflationary Economies"). TAS 29 requires that financial statements prepared in the currency of a hyperinflationary economy be presented in terms of the purchasing power of that currency at the balance sheet date and that corresponding figures for previous periods be restated in the same terms. One of the requirements to apply TAS 29 is a three-year compound inflation rate approaching or exceeding 100%. The indexation is based on a multiple derived from the Turkish Consumer Price Index published by the Turkish Statistical Institute ("TurkStat"). Since 1 January 2005, the indices and adjustment factors used in the restatement of the financial statements for the current and prior periods are as follows:

Date	Index	Correction Coefficient	3 -Year Combined Inflation Rate
30 June 2025	3,132.17	1,00000	220%
31 December 2024	2,684.55	1,16674	291%
30 June 2024	2,319.29	1,35049	324%

The main components of the restatement applied by the Company for financial reporting purposes in hyperinflationary economies are as follows:

- TRY denominated financial statements for the current period are stated in terms of the purchasing power of the currency at the balance sheet date and the amounts for previous reporting periods are restated in accordance with the purchasing power of the currency at the latest balance sheet date.
- Monetary assets and liabilities are not restated as they are currently expressed in terms of the measuring unit current at the balance sheet date. Where the inflation-adjusted amounts of non- monetary items exceed their recoverable amount or net realizable value, the provisions of TAS 36 and TAS 2 have been applied, respectively.
- Non-monetary assets, liabilities and equity items that are not expressed in the current purchasing power at the balance sheet date are restated by applying the relevant conversion factors.
- All items in the statements of income and other comprehensive income, except cost of sales, depreciation expense and gain/loss on sale of assets, have been restated by applying the relevant monthly restatement factors. Cost of sales, depreciation expense and gain/loss on sale of assets are recalculated based on the adjusted balance sheet items using the adjustment factors.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira (“TRY”) in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

2.2 Statement of Compliance to Turkish Financial Reporting Standards (“TFRS”)

The financial statements of the company have been prepared in accordance with TFRS. TFRSs include Turkish Accounting Standards (TAS), Turkish Financial Reporting Standards (TFRSs), TMS Comments and Turkey Financial Reporting Standards comprise standards and interpretations published by TAS Reviews, published by the Public Oversight, Accounting and Auditing Standards Authority (“POA”).

The attached financial statements prepared based on the Capital Markets Board Notification No II-14.1 published in the Official Gazette dated 13 June 2013 and numbered 28676, the Public Oversight, Accounting and Auditing Standards Authority (“KGG”), which was enacted by Turkey Financial Reporting Standards (“TFRSs”) as appropriate. TFRS; includes standards and comments published by the ups under the names of Turkish Accounting Standards (“TAS”), Turkish Financial Reporting Standards, TAS comments and TFRS comments.

The financial statements are presented in accordance with “Announcement regarding with TAS Taxonomy” which was published on 15 April 2019 by POA and the format and mandatory information recommended by CMB

Approval of financial statements:

The financial statements were approved by the Company's Board of Directors on 3 September 2025. General Assembly have the right to restate and other regulatory authorities have the right to demand its restatement.

2.3 Financial Statements of Comparative Information and Restatement of Prior Period

The financial statements of the Company are prepared in comparison with the previous period in order to enable the determination of financial status and performance trends. In accordance with the presentation of the current period financial statements, comparative information is reclassified and significant differences are disclosed.

2.4 Changes in significant accounting policies

The accounting policies applied in the company's interim summary consolidated financial statements are the same as those applied in its financial statements for the year ending 31 December 2024.

2.5 Summary of significant accounting policies

The interim summary financial statements for the period ending 30 June 2025 have been prepared in accordance with the TFRS standard TMS 34, which covers the preparation of interim financial statements. Furthermore, the interim summary financial statements for the period ending 30 June 2025 have been prepared using accounting policies that are consistent with those applied in the preparation of the financial statements for the year ending 31 December 2024. Therefore, these interim summary financial statements should be evaluated together with the financial statements for the year ending 31 December 2024.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

2.5 Summary of significant accounting policies (Continued)

a. Standards, amendments, and interpretations applicable as of 30 June 2025:

- **Amendments to IAS 21 - Lack of Exchangeability;** effective from annual periods beginning on or after 1 January 2025. An entity is impacted by the amendments when it has a transaction or an operation in a foreign currency that is not exchangeable into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that creates enforceable rights and obligations.

b. Standards, amendments, and interpretations that are issued but not effective as of 30 June 2025:

- **Amendment to IFRS 9 and IFRS 7 - Classification and Measurement of Financial Instruments;** effective from annual reporting periods beginning on or after 1 January 2026 (early adoption is available). These amendments:
 - clarify the requirements for the timing of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic cash transfer system;
 - clarify and add further guidance for assessing whether a financial asset meets the solely payments of principal and interest (SPPI) criterion;
 - add new disclosures for certain instruments with contractual terms that can change cash flows (such as some instruments with features linked to the achievement of environment, social and governance (ESG) targets); and
 - make updates to the disclosures for equity instruments designated at Fair Value through Other Comprehensive Income (FVOCI).
- **Annual improvements to IFRS - Volume 11;** effective from annual periods beginning on or after 1 January 2026 (earlier application permitted). Annual improvements are limited to changes that either clarify the wording in an Accounting Standard or correct relatively minor unintended consequences, oversights or conflicts between the requirements in the Accounting Standards. The 2024 amendments are to the following standards:
 - IFRS 1 First-time Adoption of International Financial Reporting Standards;
 - IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7;
 - IFRS 9 Financial Instruments;
 - IFRS 10 Consolidated Financial Statements; and
 - IAS 7 Statement of Cash Flows.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira (“TRY”) in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 2 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)

2.5 Summary of significant accounting policies (Continued)

- **Amendment to IFRS 9 and IFRS 7 - Contracts Referencing Nature-dependent Electricity;** effective from annual periods beginning on or after 1 January 2026 but can be early adopted subject to local endorsement where required. These amendments change the 'own use' and hedge accounting requirements of IFRS 9 and include targeted disclosure requirements to IFRS 7. These amendments apply only to contracts that expose an entity to variability in the underlying amount of electricity because the source of its generation depends on uncontrollable natural conditions (such as the weather). These are described as 'contracts referencing nature-dependent electricity'
- **IFRS 18 Presentation and Disclosure in Financial Statements;** effective from annual periods beginning on or after 1 January 2027. This is the new standard on presentation and disclosure in financial statements, with a focus on updates to the statement of profit or loss. The key new concepts introduced in IFRS 18 relate to:
 - the structure of the statement of profit or loss;
 - required disclosures in the financial statements for certain profit or loss performance measures that are reported outside an entity's financial statements (that is, management-defined performance measures); and
 - enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general.
- **IFRS 19 Subsidiaries without Public Accountability: Disclosures;** effective from annual periods beginning on or after 1 January 2027. This new standard works alongside other IFRS Accounting Standards. An eligible subsidiary applies the requirements in other IFRS Accounting Standards except for the disclosure requirements and instead applies the reduced disclosure requirements in IFRS 19. IFRS 19's reduced disclosure requirements balance the information needs of the users of eligible subsidiaries' financial statements with cost savings for preparers. IFRS 19 is a voluntary standard for eligible subsidiaries. A subsidiary is eligible if:
 - it does not have public accountability; and
 - it has an ultimate or intermediate parent that produces consolidated financial statements available for public use that comply with IFRS Accounting Standards.

2.6 Periodicity of Activities

Due to the decrease in food production until the start of the summer season, the Group's interim summary financial statements may also reflect the effects resulting from the seasonality of operations. Therefore, the six-month operating results for the period ending 30 June 2025 may not be indicative of the results for the entire fiscal year.

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTES 3 - FINANCIAL BORROWINGS

The details of financial borrowings as at 30 June 2025 and 31 December 2024 are as follows:

	30 June 2025	31 December 2024
Short-term loans	2,000,264,707	1,585,619,934
Short term portions of long-term loans	400,521,516	162,623,986
Short-term portions of long-term issued bonds	323,690,452	903,673,847
Short-term issued bonds	371,944,164	464,887,872
Short-term leasing liabilities	20,919,807	23,751,317
Total short-term borrowings	3,117,340,646	3,140,556,956
Long-term loans	305,258,340	434,985,119
Long-term issued bonds	216,496,207	169,765,849
Long-term leasing liabilities	77,960,020	98,805,634
Total long-term financial borrowing	599,714,567	703,556,602
Total Borrowings	3,717,055,213	3,844,113,558

As of 30 June 2025, the Company has not pledged or mortgaged any assets in relation to its financial liabilities. (31 December 2024: None).

The details of financial liabilities as at 30 June 2025 are as follows:

	The weighted average interest rate	Original amount	30 June 2025 Net book value (TRY)
Short term financial borrowings			
TRY borrowings	24.41%	729,600,000	730,687,715
USD borrowings	7.37%	17,800,000	669,387,611
EUR borrowings	7.11%	14,984,480	1,000,710,898
Bond issued and bills	49.73%	340,000,000	695,634,615
			3,096,420,839
Long term financial borrowings			
EUR borrowings	6.67%	13,538,718	252,766,620
EUR borrowings	8.74%	1,800,000	52,491,720
Bond issued and bills	48.73%	530,000,000	216,496,207
			521,754,547

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 3 - FINANCIAL BORROWINGS (Continued)

The details of financial liabilities as at 31 December 2024 are as follows:

	The weighted average interest rate	Original amount	31 December 2024 Net book value (TRY)
Short term financial borrowings			
TRY borrowings	26.78%	340,000,000	396,691,600
USD borrowings	7.22%	17,900,000	762,496,738
EUR borrowings	6.67%	10,384,480	589,055,582
Bond issued and bills	39.73%	960,000,000	1,368,561,718
			3,116,805,638
Long term financial borrowings			
EUR borrowings	7.73%	12,500,000	350,334,333
USD borrowings	8.74%	2,000,000	84,650,786
Bond issued and bills	50.82%	230,000,000	169,765,849
			604,750,968

As at 30 June 2025 and 31 December 2024, long-term loans denominated in TRY currency payment plan is as follows:

	30 June 2025	31 December 2024
To be paid on demand or within 1 year	3,096,420,839	3,116,805,638
1-2 years	521,754,547	604,750,968
	3,618,175,386	3,721,556,606

As at 30 June 2025 and 31 December 2024, long-term leasing liabilities payment plan is as follows:

	30 June 2025	31 December 2024
To be paid on demand or within 1 year	20,919,807	23,751,317
1-2 years	11,509,693	13,651,756
2-3 years	11,676,470	12,364,097
3-4 years	14,913,533	15,389,257
4-5 years	19,121,384	19,692,877
More than 5 years	20,738,940	37,707,647
	98,879,827	122,556,951

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 4 - TRADE RECEIVABLES AND PAYABLES

Trade Receivables

The details of trade receivables are as follows as at 30 June 2025 and 31 December 2024:

	30 June 2025	31 December 2024
Trade receivables from related parties (Note 16)	43,211,918	27,499,548
Trade Receivables	1,389,735,563	1,193,597,230
Provisions for doubtful receivables	(17,173,485)	(20,036,992)
	1,415,773,996	1,201,059,786

The movement of the provision for doubtful receivables or the periods as of 1 January - 30 June 2025 and 1 January - 31 December is as follows:

	1 January - 30 June 2025	1 January - 31 December 2024
Opening balance	(20,036,992)	(16,186,514)
Addition during period, net	-	(8,825,907)
Monetary Gain/Loss	2,863,507	4,975,429
	(17,173,485)	(20,036,992)

Information on the nature and level of risk in trade receivables is disclosed in Note 18.

Trade Payables

As at 30 June 2025 and 31 December 2024, details of trade payables are as follows:

	30 June 2025	31 December 2024
Trade payables		
Suppliers	659,506,843	1,043,241,433
Trade payables to related parties (Note 16)	20,985,615	9,298,733
	680,492,458	1,052,540,166

NOTE 5 - INVENTORIES

As of 30 June 2025 and 31 December 2024, the details of inventories are as follows:

	30 June 2025	31 December 2024
Raw material	548,633,987	500,137,096
Finished goods	1,708,771,293	3,672,798,706
Work in progress	16,918,736	43,332,206
Other inventory	2,901,905	4,658,008
Less: Provision for Impairment of Inventories	(5,700,335)	(20,188,094)
	2,271,525,586	4,200,737,922

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 6 - PROPERTY, PLANT AND EQUIPMENT

The movements of property, plant and equipment and depreciation for the periods ended 30 June 2025 and 31 December 2024 are as follows:

	1 January - 30 June 2025	1 January - 30 June 2024
Net book value as of 1 January	2,537,226,908	2,381,941,659
Additions	90,916,647	110,302,315
Disposals	(54,312)	(1,027,712)
Transfers	(4,882,115)	(4,119,208)
Current period depreciation	(52,363,506)	(55,019,050)
	2,570,843,622	2,432,078,004

NOTE 7 - COMMITMENTS AND OBLIGATIONS

The guarantees and contingent liabilities provided by the Company on behalf of related parties, the parent company, or third parties within the scope of its commercial activities are as follows:

	30 June 2025	31 December 2024
A. Given on behalf of own legal entity	1,292,582,438	1,006,351,306
B. Given in favor of joint ventures	-	-
C. Given to third parties for the purpose of carrying out ordinary commercial activities	-	-
- Given on behalf of main partner	-	-
- Given in favor of other group companies not in the scope of clauses B and C	-	-
- Given in favor of third parties not covered by clause C	-	-
D. Other	-	-
	1,292,582,438	1,006,351,306

The Company has various guarantee letters issued to tax authorities (related to VAT refund receivables), T. İhracat Kredi Bankası A.Ş. and customs which are amounting to TRY1,292,582,438 (31 December 2024: TRY1,006,351,306).

All guarantees are given by the company are in local currency and there is no any pledges and mortgages given.

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 8 - EQUITY

a) Capital

As of 30 June 2025 the capital adjustment differences amounting to TRY244,800,000 consist of capital adjustment differences resulting from the restatement of the Company's paid-in capital amount and that are not offset to the previous years' losses or added to the share capital (31 December 2024: TRY13,6000,000,000).

The Company's shareholders and their shares in capital as of 30 June 2025 and 31 December 2024 are as follows with historical values:

	%	30 June 2025	%	31 December 2024
Memişoğlu Tarım Ürünleri Tic. Ltd. Şti.	51.93	127,128,087	49.84	67,788,852
Halka açık	40.85	100,003,288	40.60	55,217,844
Temel Ticaret ve Yatırım A.Ş.	3.26	7,970,200	3.26	4,427,889
Kagome Co. Ltd.	2.07	5,071,168	3.73	5,071,168
Sumitomo Corporation	0.85	2,077,983	1.53	2,077,983
Others	1.04	2,549,274	1.04	1,416,264
Total Share Capital	100.00	244,800.000	100,00	136,000,000
Capital Inflation Adjustment		3,320,174,466		3,308,115,074
Adjusted Capital		3,564,974,466		3,444,115,074

There are no privileges, rights or limitations between the shares representing the capital of the Company.

The Company has adopted the registered capital system in accordance with the provisions of the Capital Market Law ("CMB") No: 6362 and passed to this system with the permission of the Capital Markets Board ("CMB") dated 20 August 1992 and numbered 454. The registered capital ceiling of the Company is TRY250,000,000 and each kurus consists of 25,000,000,000 shares with a nominal value.

As of 30 June 2025, capital adjustment differences amounting to TRY2,414,177,792 consist of capital adjustment differences resulting from the restatement of the Company's paid-in capital amount and that are not offset to the previous years' losses or added to the share capital (31 December 2024: TRY2,795,739,817).

The nominal values and inflation adjustment effects of the following equity items in accordance with TFRS and TPL as of 30 June 2025 are as follows::

30 June 2025 (TFRS)	Nominal Value	Inflation adjustment effect	Indexed value
Capital	244,800,000	3,320,174,466	3,564,974,466
Share premiums	69,547,881	7,708,440	77,256,321
Legal reserves	119,908,083	912,204,310	1,032,112,393
30 June 2025 (TPL)	Nominal Value	Inflation adjustment effect	Indexed value
Capital	244,800,000	4,449,702,991	4,694,502,991
Share premiums	79,655,690	235,425,924	315,081,614
Legal reserves	119,908,083	830,876,254	950,784,337

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 8 - EQUITY (Continued)**b) Share premium**

These premiums related to the shares that have been canceled by not participating in the capital increase are positive differences on the shares sold above the nominal value. As at 30 June 2025, the share of the Company's share in the financial statements is TRY77,256,321 (31 December 2024: TRY0).

c) Restricted reserves

Reserves reserved for specific purposes other than profit from previous periods, due to law or contractual obligations or other profit distribution.

These reserves are presented in the prepared in accordance with the Tax Procedure Law Company's statutory records and the differences in preparing the financial statements in accordance with TFRS are associated with prior years' profits.

As of 30 June 2025 and 31 December 2024 the Company's details of restricted reserves are as follows:

	30 June 2025	31 December 2024
Legal reserves	64,064,168	64,063,591
Special reserves	968,048,225	968,048,802
Total	1,032,112,393	1,032,112,393

Legal Reserves

The legal reserves consist of first and second legal reserves, appropriated in accordance with the Turkish Commercial Code, are not distributable to shareholders. The first legal reserve is appropriated out of historical statutory profits at the rate of 5% per annum, until the total reserve reaches 20% of the historical paid-in share capital. The second legal reserve is appropriated after the first legal reserve and dividends, at the rate of 10% per annum of all cash dividend distributions.

Such reserves can be used to take measures suitable for continuing the business or preventing unemployment and mitigating the results only when the losses are not going well, unless the Company's capital exceeds half of the paid capital.

Special Reserves

According to the article 5/1-e of Corporate Tax Law No: 5520, 75% of the earnings from the sale of the properties and participation shares that corporations have kept among their assets for at least two full years, and from the sales of founders' shares, preference shares and preferred rights they have kept for same duration are exempted from corporate tax. This exception shall apply in the term the sale is made, and the part of the proceeds of the sale that benefited from the exception shall be kept in a special fund account of liabilities, until the end of the fifth year following the sale. However, the sale price must be collected until the end of the second calendar year following the year the sale is made.

d) Dividend distribution

The Company does not distribute dividends.

TAT GIDA SANAYİ A.Ş.**EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025**

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 9 - SALES AND COST OF SALES

The details of revenue and cost of sales for the periods 1 January - 30 June 2025 and 2024 as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Domestic sales (net)	2,531,878,883	2,421,692,782	1,195,618,621	1,080,649,636
Foreign sales (net)	984,026,738	1,717,487,853	496,364,678	803,248,703
Net sales	3,515,905,621	4,139,180,635	1,691,983,299	1,883,898,339
Raw material costs	(668,544,903)	(655,676,291)	(411,915,246)	(329,846,418)
Labor costs	(158,187,114)	(172,658,972)	(80,042,787)	(96,011,935)
General overhead costs	(126,834,336)	(148,334,146)	(73,445,547)	(74,666,089)
Depreciation costs	(19,837,405)	(17,957,029)	(13,185,935)	(1,016,979)
Less: change in inventory	(1,964,027,413)	(2,434,981,914)	(795,540,547)	(1,012,359,165)
Cost of goods sold	(2,937,431,171)	(3,429,608,352)	(1,374,130,062)	(1,513,900,586)
Trade goods sold	(66,458,280)	(187,046,667)	(33,526,929)	(126,297,374)
Other cost of sales	(118,808,641)	(219,943,268)	(53,025,190)	(79,440,917)
Cost of sales (-)	(3,122,698,092)	(3,836,598,287)	(1,460,682,181)	(1,719,638,877)
Gross profit	393,207,529	302,582,348	231,301,118	164,259,462

NOTE 10 - EXPENSES BY NATURE

Details of research and development expenses for the periods 1 January – 30 June 2025 and 2024 as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Research and development expenses				
Personnel expenses	(8,034,995)	(12,698,169)	(3,724,257)	(5,825,402)
Depreciation expenses	(1,024,045)	(1,739,688)	(515,086)	(1,417,235)
Other	(1,896,695)	(2,102,903)	(1,490,146)	(1,633,748)
	(10,955,735)	(16,540,760)	(5,729,489)	(8,876,385)

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 10 - EXPENSES BY NATURE (Continued)

As at 1 January - 30 June 2025 and 2024 the details of general and administrative expenses are as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Marketing, sales and distribution expenses:				
Personnel expenses	(80,519,177)	(106,349,604)	(38,424,298)	(44,135,368)
Shipping and insurance expenses	(79,250,112)	(91,395,932)	(35,224,704)	(42,047,144)
Advertising expenses	(19,790,745)	(49,884,807)	(15,417,183)	(17,363,475)
Export expenses	(24,805,492)	(32,057,153)	(11,019,265)	(10,674,230)
Subcontracting expenses	(17,877,364)	(27,125,812)	(8,741,776)	(12,719,359)
Sales support expenses	(385,217)	(21,489,172)	(385,217)	(8,765,133)
Other	(11,855,140)	(26,543,493)	(6,430,413)	(8,325,063)
	(234,483,247)	(354,845,973)	(115,642,856)	(144,029,772)

As at 1 January - 30 June 2025 and 2024 details of research and development expenses are as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
General and administrative expenses:				
Personnel expenses	(95,787,919)	(132,709,025)	(49,337,093)	(41,763,899)
Depreciation and amortization	(53,518,588)	(65,128,818)	(26,611,346)	(50,925,537)
Information technology expenses	(16,787,521)	(27,466,948)	(9,258,230)	(9,770,921)
Administrative expenses	(10,699,582)	(15,065,456)	(5,389,222)	(7,405,841)
Severance expense	(4,321,865)	(37,840,870)	(2,275,474)	(1,851,233)
Tax and duties expenses	(5,101,660)	(8,542,759)	(1,762,377)	(5,779,415)
Transport, travel expenses	(3,588,428)	(6,797,131)	(1,466,410)	(2,799,566)
Consultancy and lawsuit expenses	(2,017,083)	(11,549,136)	(898,792)	(2,290,523)
Repair and maintenance expenses	(1,279,343)	(1,728,082)	(926,064)	(641,318)
Other	(7,105,374)	(11,964,862)	(3,608,732)	(4,501,674)
	(200,207,363)	(318,793,087)	(101,533,740)	(127,729,927)

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 11 - OTHER INCOME AND EXPENSES FROM OPERATING ACTIVITIES

As at 1 January - 30 June 2025 and 2024 details of other income and profits from operating activities are as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Other Operating Income				
Interest income on trade receivables due to maturity differences	143,457,560	274,812,528	66,550,670	135,933,594
Foreign exchange gain on trading activities	58,062,596	56,215,788	33,215,035	11,628,598
Others	22,409,652	24,667,936	11,400,373	15,996,525
	223,929,808	355,696,252	111,166,078	163,558,717

As at 1 January - 30 June 2025 and 2024 details of other expenses and losses from operating activities are as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Other Operating Income				
Term differences interest income of trading activities	(53,336,787)	(100,127,635)	(25,175,310)	(44,348,545)
Foreign exchange loss on trading activities	(15,523,098)	(17,648,781)	(5,873,924)	(8,768,338)
Others	(9,195,489)	(1,171,654)	(7,683,466)	(129,537)
	(78,055,374)	(118,948,070)	(38,732,700)	(53,246,420)

NOTE 12 - INCOME AND EXPENSES FROM INVESTING ACTIVITIES

As at 1 January - 30 June 2025 and 2024 investment income and profits from operations is as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Income from Investing Activities				
Gain on sale of property, plant and equipment	270,642	5,652,522	96,970	3,222,807
Rental income	-	4,375,840	-	3,691,487
	270,642	10,028,362	96,970	6,914,294

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 13 - FINANCIAL INCOME AND EXPENSES

As at 1 January - 30 June 2025 and 2024 financial incomes are as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Foreign exchange gains	30,801,232	16,559,407	24,076,094	4,415,876
Interest income on bank deposits	63,867,975	27,397,499	44,301,726	17,027,258
Export foreign exchange conversion incentive revenues	6,213,242	-	3,714,391	-
	100,882,449	43,956,906	72,092,211	21,443,134

As at 1 January - 30 June 2025 and 2024 financial expenses are as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Foreign exchange expenses	(260,728,200)	(34,591,343)	(145,537,696)	(20,125,685)
Bond interest expense	(242,284,839)	(516,134,390)	(108,943,773)	(250,013,074)
Bank loans interest expense	(167,303,457)	(169,119,622)	(66,941,730)	(78,724,456)
Leasing liabilities interest expenses	(14,252,876)	(16,334,403)	(6,750,866)	(7,418,343)
Other	(25,110,853)	(48,091,010)	(11,721,792)	(30,885,147)
	(709,680,225)	(784,270,768)	(339,895,857)	(387,166,705)

NOTE 14 - TAX ASSESTS AND LIABILITIES

As at 1 January - 30 June 2025 and 2024 tax assets and liabilities are as follows:

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Deferred tax (income) / expense	69,982,730	(44,284,155)	77,926,527	2,138,522
Current tax (income) / expense	-	-	-	1,300,213
Total tax expense	69,982,730	(44,284,155)	77,926,527	3,438,735

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 15 - OTHER ASSETS

As at 30 June 2025 and 31 December 2024 other assets are as follows:

	30 June 2025	31 December 2024
Other current assets		
VAT transferred	169,426,917	418,848,479
Export tomato incentive	44,754,685	-
Income accruals	22,893,212	5,680,488
VAT receivables arising from exports	4,022,855	4,689,391
Others	11,015,655	430,294
	252,113,324	429,648,652
	30 June 2025	31 December 2024
Other non - current assets:		
Fixed asset advance paid	33,121,334	5,008,395
	33,121,334	5,008,395

NOTE 16 - RELATED PARTY TRANSACTIONS

a) Receivables from related parties

	30 June 2025	31 December 2024
Memişoğlu Tarım Ürünleri Tic. Ltd. Şti.	42,684,615	26,327,873
Tat Bakliyat San.ve Tic. A.Ş.	527,303	931,647
Tatlog Lojistik Hizmetleri A.Ş.	-	240,028
	43,211,918	27,499,548

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 16 - RELATED PARTY TRANSACTIONS(Continued)

b) Payables to related parties:

Trade payables	30 June 2025	31 December 2024
Tatlog Lojistik Hizmetleri A.Ş.	10,242,055	8,257,359
Temel Ticaret Yatırım A.Ş.	8,488,685	1,041,374
Memişoğlu Tarım Ürünleri Tic. Ltd. Şti.	2,254,875	-
	20,985,615	9,298,733
Other payables	30 June 2025	31 December 2024
Memişoğlu Tarım Ürünleri Tic. Ltd. Şti.	-	70,934,162
Total trade and other payables	20,985,615	80,232,895
Leasing borrowings	30 June 2025	31 December 2024
Temel Ticaret ve Yatırım A.Ş.	3,328,959	-
Memişoğlu Tarım Ürünleri Tic. Ltd. Şti.	-	545,930
Total leasing borrowings	3,328,959	545,930

i) As at 1 January - 30 June 2025 and 2024 the details of financial income and expenses from/to related parties are as follows:

a) Product sales to related parties

	1 January - 30 June 2025	1 January - 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Memişoğlu Tarım Ürünleri Tic. Ltd. Şti.	112,044,891	322,569,255	57,846,857	218,500,202
Tat Bakliyat San.ve Tic. A.Ş.	30,701,710	26,515,321	18,436,532	23,873,433
	142,746,601	349,084,576	76,283,389	242,373,635

Purchases from related parties:

	1 January- 30 June 2025	1 January- 30 June 2024	1 April - 30 June 2025	1 April - 30 June 2024
Memişoğlu Tarım Ürünleri Tic. Ltd. Şti.	43,139,238	68,963,794	22,796,696	45,788,667

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 16 - RELATED PARTY TRANSACTIONS(Continued)

c) Service purchases from related parties:

	1 January- 30 June 2025	1 January- 30 June 2024	1 April-30 June 2025	1 April-30 June 2024
Tatlog Lojistik Hizmetleri A.Ş.	57,612,497	-	31,817,956	-
Temel Ticaret ve Yatırım A.Ş.	8,913,133	5,231,555	4,305,112	2,492,067
Memişoğlu Tarım Ürünleri Tic. Ltd Şti.	533,334	-	207,629	-
	67,058,964	5,231,555	36,330,697	2,492,067

a) Compensation paid to the members of the Board of Directors and key management personnel

Senior executives of Tat Gıda are determined as the Chairman and Members of the Board of Directors, General Manager, Assistant General Managers and Directors directly affiliated with the General Manager. For the 6-month period ended 30 June 2025 the total of benefits provided to Tat Gıda's senior executives is TRY28,702,602 (31 December 2024: TRY100,414,369). All of the payments are short-term in nature and do not include separation payments.)

TAT GIDA SANAYİ A.Ş.**EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025**

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 17 - EXPLANATIONS REGARDING NET MONETARY POSITION GAINS / (LOSSES)

Non-monetary Items	30 June 2025
Statement of Financial Position Items	8,455,678
Inventories	214,386,784
Advances given	23,300,312
Subsidiaries	562,900
Property, plant and equipment	286,647,924
Intangible assets	22,214,386
Right of use assets	22,775,144
Advances received	(1,018,120)
Deferred tax liabilities	(17,153,087)
Share capital	(504,258,941)
Premiums related to shares	(7,708,440)
Changes in fair value	44,455,846
Gains/losses on remeasurement of defined benefit plans	4,160,227
Restricted profit reserves	(147,500,232)
Retained Earnings/Accumulated Losses	67,590,975
Profit and Loss Statement Items	343,724,864
Sales	(165,549,967)
Cost of sales	440,359,807
Marketing expenses	10,353,563
General administrative expenses	34,742,228
Research expenses	873,598
Other income from operating activities	(10,683,749)
Other expense from operating activities	3,701,967
Income from investing activities	(11,625)
Finance income	(3,502,116)
Finance expense	33,441,158
NET MONETARY POSITION GAIN	352,180,542

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 18 - NATURE AND THE LEVEL OF RISK RESULTED FROM FINANCIAL INSTRUMENTS

a) Capital Risk Management

The Company's principal financial risks arising from its operations are market risk (including currency risk, fair value interest rate risk, and price risk), credit risk, liquidity risk, and cash flow interest rate risk. The Company's risk management program generally seeks to minimize the effects of uncertainty in financial market on financial performance of the Company. The Company uses derivative financial instruments in order to safeguard itself from different financial risks.

Risk management is implemented by finance department according to the policies approved by Board of Directors. The Company's finance department provides services to the business, co-ordinates access to domestic and international financial markets, monitors and manages the financial risks relating to the operations of the Company through internal risk reports which analyses exposures by degree and magnitude of risks. The written procedures are formed by Board of Directors to manage the foreign currency risk, interest risk, credit risk, use of derivative and non-derivative financial instruments and the assessment of excess liquidity.

There are not any changes in financial risk factors and credit risk management of the Company as compared to previous year.

a.1) Credit risk management

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the Company. The Company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults. The Company manages this risk by the credit limits up to the guarantees received from customers. The usage of credit limits are monitored by the Company according to the customer's credibility is evaluated continuously. Trade receivables consist of many customers that operate in various industries and locations. Credit risk of the receivables from counterparties are evaluated perpetually.

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 18 - NATURE AND THE LEVEL OF RISK RESULTED FROM FINANCIAL INSTRUMENTS (Continued)

30 June 2025	Receivables				Deposit in Banks	Derivatives
	<u>Trade Receivables</u>		<u>Other Receivables</u>			
	Related Party	Third Party	Related Party	Third Party		
Maximum credit risk exposure as of the reporting date (A+B+C+D+E)	43,211,918	1,372,562,078	-	7,322,533	1,030,637,803	-
- The portion of the maximum risk guaranteed by collateral	-	207,575,680	-	-	-	-
A. Net book value of financial assets not overdue financial or impaired	-	922,691,349	-	7,322,533	1,030,637,803	-
B. Renegotiated conditions; otherwise, the carrying amount of financial assets that are overdue or impaired	-	-	-	-	-	-
C. Carrying value of financial assets that are past due but not impaired	43,211,918	449,870,729	-	-	-	-
- Collateral, etc. secured part	-	92,829,443	-	-	-	-
D. Net book value of impaired assets	-	-	-	-	-	-
- Overdue (gross book value)	-	17,173,485	-	-	-	-
- Impairment (-)	-	(17,173,485)	-	-	-	-
- Not overdue (gross book value)	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-
E. Off-balances sheet items with credit risk	-	-	-	-	-	-

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira (“TRY”) in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 18 - NATURE AND THE LEVEL OF RISK RESULTED FROM FINANCIAL INSTRUMENTS (Continued)

	Receivables					
	<u>Trade Receivables</u>		<u>Other Receivables</u>			
31 December 2024	Related Party	Third Party	Related Party	Third Party	Deposit in Banks	Derivatives
Maximum credit risk exposure as of the reporting date (A+B+C+D+E)	27,499,548	1,173,560,238	-	3,422,814	137,241,800	-
- The portion of the maximum risk guaranteed by collateral	-	154,783,916	-	-	-	-
A. Net book value of financial assets not overdue or impaired	-	723,445,842	-	3,422,814	137,241,800	-
B. Conditions found in re-interviewed. otherwise, the carrying amount of financial assets overdue or impaired	-	-	-	-	-	-
C. Carrying value of financial assets that are past due but not impaired	27,499,548	450,114,396	-	-	-	-
- Collateral, etc. secured part	-	62,317,981	-	-	-	-
D. Net book value of impaired assets	-	-	-	-	-	-
- Overdue (gross book value)	-	20,036,992	-	-	-	-
- Impairment (-)	-	(20,036,992)	-	-	-	-
- Not overdue (gross book value)	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-
E. Off-balances sheet items with credit risk	-	-	-	-	-	-

TAT GIDA SANAYİ A.Ş.**EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025**

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 18 - NATURE AND THE LEVEL OF RISK RESULTED FROM FINANCIAL INSTRUMENTS (Continued)***a.2) Foreign currency risk management***

Transactions in foreign currencies cause foreign currency risk. Currency risk is managing by foreign currency purchase/sale contracts based on the approved policies.

The foreign currency denominated assets and liabilities of monetary and non-monetary items are as follows:

30 June 2025	TRY Equivalent	USD	EUR	GBP
1 Trade receivables	329,567,523	3,479,750	4,103,796	225
2.a Monetary financial assets	300,256,103	3,961,830	3,046,690	14,924
2.b Non - monetary financial assets	-	-	-	-
3.Other	-	-	-	-
4.CURRENT ASSETS (1+2+3)	629,823,626	7,441,580	7,150,486	15,149
5.Trade receivables	-	-	-	-
6.a Monetary financial assets	-	-	-	-
6.b Non - monetary financial assets	-	-	-	-
7.Other	-	-	-	-
8.NON - CURRENT ASSETS (5+6+7)	-	-	-	-
9.TOTAL ASSETS (4+8)	629,823,626	7,441,580	7,150,486	15,149
10. Trade payables	28,546,990	494,760	189,472	50
11. Financial liabilities	1,468,754,671	15,800,000	17,984,480	-
12.a Other monetary liabilities	3,088,501	9,720	57,859	-
12.b Other non - monetary financial liabilities	34,762,022	873,146	-	-
13. CURRENT LIABILITIES (10+11+12)	1,535,152,184	17,177,626	18,231,811	50
14. Trade payables	-	-	-	-
15. Financial liabilities	-	-	-	-
16.a Other monetary liabilities	1,190,871	-	25,505	-
16.b Other non - monetary financial liabilities	-	-	-	-
17. NON-CURRENT LIABILITIES (14+15+16)	1,190,871	-	25,505	-
18. TOTAL LIABILITIES (13+17)	1,536,343,056	17,177,626	18,257,316	50
19 Net asset/liability position of off - balance sheet derivatives (19a-19b)	-	-	-	-
19.a Off - balance sheet foreign currency derivative asset	-	-	-	-
19.b Off - balance sheet foreign currency derivative liabilities	-	-	-	-
20. Net foreign currency asset/liability position (9-18+ 19)	(906,519,430)	(9,736,046)	(11,106,830)	15,099
21. Net foreign currency asset / liability position of monetary items (1+2a+6a-10-11-12a-14-15-16a)	(871,757,408)	(8,862,900)	(11,106,830)	15,099
22. Fair value of foreign currency hedged financial assets	-	-	-	-
23. Hedged foreign currency assets	-	-	-	-
24. Hedged foreign currency liabilities	-	-	-	-

TAT GIDA SANAYİ A.Ş.**EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025**

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 18 - NATURE AND THE LEVEL OF RISK RESULTED FROM FINANCIAL INSTRUMENTS (Continued)

31 December 2024	TRY Equivalent	USD	EUR	GBP
1 Trade receivables	247,570,439	2,011,712	3,796,542	39,486
2.a Monetary financial assets	18,968,385	108,508	332,782	4,621
2.b Non - monetary financial assets	-	-	-	-
3.Other	-	-	-	-
4. CURRENT ASSETS(1+2+3)	266,538,824	2,120,220	4,129,324	44,107
5.Trade receivables	-	-	-	-
6.a Monetary financial assets	-	-	-	-
6.b Non - monetary financial assets	-	-	-	-
7.Other	-	-	-	-
8. NON - CURRENT ASSETS (5+6+7)	-	-	-	-
9. TOTAL ASSETS	266,538,824	2,120,220	4,129,324	44,107
10. Trade payables	95,090,613	1,644,859	631,484	2,823
11. Financial liabilities	1,828,336,318	20,266,010	23,117,218	-
12.a Other monetary liabilities	656,590	15,922	-	-
12.b Other non - monetary financial liabilities	23,428,625	568,145	-	-
13. CURRENT LIABILITIES (10+11+12)	1,947,512,146	22,494,936	23,748,702	2,823
14. Trade payables	-	-	-	-
15. Financial liabilities	-	-	-	-
16.a Other monetary liabilities	1,373,136	33,299	-	-
16.b Other non - monetary financial liabilities	-	-	-	-
17. NON-CURRENT LIABILITIES (14+15+16)	1,373,136	33,299	-	-
18. TOTAL LIABILITIES (13+17)	1,948,885,282	22,528,235	23,748,702	2,823
19. Net asset/liability position of off - balance sheet derivatives (19a-19b)	-	-	-	-
19.a Off - balance sheet foreign currency derivative assets	-	-	-	-
19.b Off - balance sheet foreign currency derivative liabilities	-	-	-	-
20. Net foreign currency asset/liability position (9-18+ 19)	(1,682,346,458)	(20,408,015)	(19,619,378)	41,284
21. Net foreign currency asset / liability position of monetary items (1+2a+6a-10-11-12a-14-15-16a)	(1,658,917,833)	(19,839,870)	(19,619,378)	41,284
22. Fair value of foreign currency hedged financial assets	-	-	-	-
23. Hedged foreign currency assets	-	-	-	-
24. Hedged foreign currency liabilities	-	-	-	-

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 18 - NATURE AND THE LEVEL OF RISK RESULTED FROM FINANCIAL INSTRUMENTS (Continued)Currency risk sensitivity

The Company is mainly exposed to foreign currency risk in USD, GBP and EUR.

The following table details the Company's sensitivity to a 20% increase and decrease in the USD, GBP and EUR. 20% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the possible change in foreign exchange rates. The sensitivity analysis only includes outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 20% change in foreign currency rates. The sensitivity analysis includes external loans as well as loans to foreign operations within the Company where the denomination of the loan is in a currency other than the currency of the lender or the borrower. A positive number indicates an increase in profit/loss and other equity.

	30 June 2025	
	Profit/ Loss	
	Appreciation of foreign currency	Devaluation of foreign currency
In the case of appreciation of USD at 20% ratio compared to TRY		
1 - USD net asset/liability	(70,570,665)	70,570,665
2- Part of hedged from USD risk (-)	-	-
3- USD net effect	(70,570,665)	70,570,665
In the case of appreciation of USD at 20% ratio compared to TRY		
4 - EUR net asset/liability	(88,437,912)	88,437,912
5 - Part of hedged from EUR risk (-)	-	-
6- EUR net effect	(88,437,912)	88,437,912
In the case of appreciation of GBP at 20% ratio compared to TRY		
7 - GBP net asset/liability	165,058	(165,058)
8 - Part of hedged from GBP risk (-)	-	-
9 - GBP net effect	165,058	(165,058)
TOTAL	(158,843,519)	158,843,519

TAT GIDA SANAYİ A.Ş.

EXPLANATORY NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS FOR THE 30 JUNE 2025

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY") in terms of the purchasing power of the Turkish Lira as of 30 June 2025.)

NOTE 18 - NATURE AND THE LEVEL OF RISK RESULTED FROM FINANCIAL INSTRUMENTS (Continued)

	31 December 2024	
	Kar / Zarar	
	Appreciation of foreign currency	Devaluation of foreign currency
In the case of appreciation of USD at 20% ratio compared to TRY		
1 - USD net asset/liability	(168,313,166)	168,313,166
2- Part of hedged from USD risk (-)	-	-
3- USD net effect	(168,313,166)	168,313,166
In the case of appreciation of EUR at 20% ratio compared to TRY		
4 - EUR net asset/liability	(168,486,635)	168,486,635
5 - EUR net asset/liability	-	-
6- EUR net effect	(168,486,635)	168,486,635
In the case of appreciation of GBP at 20% ratio compared to TRY		
7 - GBP net asset/liability	428,093	(428,093)
8 - Part of hedged from GBP risk (-)	-	-
9 - GBP net effect	428,093	(428,093)
TOTAL	(336,371,708)	336,371,708

NOTE 19 - SUBSEQUENT EVENTS

In the special situation announcement dated 31 July 2025, the Company stated that an agreement was signed on 31 July 2025 with Solares Renewable Energy Inc. for the construction of a Solar Power Plant in Çiçektepe village, Dinar district of Afyonkarahisar province, to supply the electricity requirements of the Company's production facilities from renewable energy sources. The Afyonkarahisar Solar Power Plant, with an installed capacity of approximately 9,924 kWp, is expected to require an investment of around 3.8 million USD and to generate approximately 16,000 MWh/year of electrical energy. It was announced that upon completion of the Afyonkarahisar Solar Power Plant, which is planned to be completed within the next six months, approximately 97% of the Company's actual energy consumption calculated based on the 2024 energy usage will be met from renewable energy sources.

.....